Mon, Jun. 6, 12:48 PM
Mon, Jun. 6, 11:10 AM
- Thinly traded micro cap Mirati Therapeutics (MRTX -40.1%) plummets in early trading on a 6x surge in volume in response to its update on its clinical trials. The company reported results from a Phase 1b study evaluating lead product glesatinib, a tyrosine kinase inhibitor that selectively targets certain genetic profiles of lung cancer patients called MET and Axl, in 22 subjects with non-small cell lung cancer (NSCLC).
- 11 of the 22 participants had genetic driver alterations similar to the selection criteria for the company's ongoing Phase 2 study. Tumor regression was observed in 10 of the 11 (90.9%), but only three (27.3%) were partial responders pre RECIST criteria.
- Side effects appeared to be a problem, however. Nine of the 11 subjects (81.8%) experienced dose reductions and or dose interruptions. Four of the nine experienced one reduction, two had two reductions and three had multiple reductions while on study. Eight of the subjects are no longer on trial: five discontinued due to disease progression, two related to adverse events and one withdrew consent. The dose reductions were due primarily to episodes of diarrhea. According to the company, the likely culprit was the presence of a castor oil-like ingredient in glesatinib's formulation called miglyol.
- To address the problem, a new spray-dried dispersion formulation of glesatinib is being implemented in the Phase 2 study. One partial responder who moved to the new formulation has shown an improved response and remains on study but at a dose of 500 mg twice daily, lower that the established dose of 750 mg twice daily. According to clinicaltrials.gov, the estimated final data collection date for the primary endpoint is July 2017. The estimated study completion date is July 2018.
Mon, Jun. 6, 11:01 AM
Mon, Jun. 6, 9:15 AM
Fri, May 6, 12:45 PM
Sep. 11, 2015, 12:44 PM
Jun. 1, 2015, 11:43 AM
- Thinly traded Mirati Therapeutics (MRTX -17.2%) slumps on a 7x surge in volume in response to the presentation of an abstract (#2589) at ASCO on a Phase 1 trial of its tyrosine kinase inhibitor, MGCD265, in heavily pretreated patients with non-small cell lung cancer (NSCLC) with MET gene mutations.
- According to investigators, MGCD265 showed anti-tumor activity and clinical benefit (improvements in pain and shortness of breath) in the first three patients treated, but none met RECIST criteria for responses, which is the metric used in clinical trials.
- RECIST (Response Evaluation Criteria in Solid Tumors) is a standardized method to measure the change in tumor burden.
Dec. 18, 2013, 10:03 AM
- Susquehanna starts Acadia Healthcare (ACHC +1.3%) at Positive. Price target is $56.
- Jefferies starts Mirati Therapeutics (MRTX +1.9%) at Buy. Price target is $36.
- KeyBanc initiates DaVita (DVA +1.5%) at Buy. Price target is $73.
- JMP starts Illumina (ILMN +1.1%) at Market Outperform. Price target is $125.
- KeyBanc starts IPC (IPCM -0.6%) at Hold.
- KeyBanc starts Envision Healthcare (EVHC +1.6%) at Buy. Price target is $40.
- JMP starts Quest Diagnostics (DGX -0.9%) at Market Perform.
- KeyBanc starts Team Health (TMH -0.8%) at Hold.
- JMP starts Lab Corp (LH -0.3%) at Market Perform.
- Goldman upgrades HCA Holdings (HCA +1.6%) to Conviction Buy.
- MKM downgrades Targacept (TRGT -3.1%) to Neutral from Buy.
Oct. 24, 2013, 9:18 PM
Mirati Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing a pipeline of targeted oncology products. It also focuses on its development programs on drugs intended to treat specific subsets of cancer patients with unmet needs. Its pipeline consists of... More
Industry: Drug Related Products
Country: United States